SEC Form 4 · accession 0001209191-18-037724
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Bowden
Officer — Chief Medical Officer
Period of report
Jun 12, 2018
Accepted (ET)
Jun 14, 2018 · 4:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Jun 12, 2018 | M | 2,000 | $35.16 | A | 2,881 | D | |
| Common stockF3 | Jun 12, 2018 | S | 1,800 | $92.84 | D | 1,081 | D | |
| Common stockF4 | Jun 12, 2018 | S | 200 | $93.37 | D | 881 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F5 | $35.16 | Jun 12, 2018 | M | 2,000 | D | — | May 30, 2024 | Common stock | 2,000 | 95,000 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F3The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $92.28 to $93.08. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $93.31 to $93.52. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.